2. Academic Validation
  3. Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity

Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity

  • Curr Opin Virol. 2021 Dec:51:179-189. doi: 10.1016/j.coviro.2021.10.007.
Amanda N Pinski 1,  Ilhem Messaoudi 2
Affiliations

Affiliations

  • 1 Department of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA, USA.
  • 2 Department of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA, USA; Center for Virus Research, University of California, Irvine, Irvine, CA, USA; Institute for Immunology, University of California, Irvine, Irvine, CA, USA; Department of Microbiology, Immunology and Molecular Genetics, College of Medicine, University of Kentucky, Lexington, KY, USA. Electronic address: [email protected].
PMID: 34749265 DOI: 10.1016/j.coviro.2021.10.007
Abstract

Zaire Ebola virus (EBOV) is a member of the Filoviridae family. Infection with EBOV causes Ebola virus disease (EVD) characterized by excessive inflammation, lymphocyte death, coagulopathy, and multi-organ failure. In 2019, the FDA-approved the first anti-EBOV vaccine, rVSV-EBOV-GP (Ervebo® by Merck). This live-recombinant vaccine confers both prophylactic and therapeutic protection to nonhuman primates and humans. While mechanisms conferring prophylactic protection are well-investigated, those underlying protection conferred shortly before and after exposure to EBOV remain poorly understood. In this review, we review data from in vitro and in vivo studies analyzing early immune responses to rVSV-EBOV-GP and discuss the role of innate immune activation in therapeutic protection.

Figures